Plaintiffs argue that companies like Novo Nordisk and Eli Lilly ignored clinical trial data, post-marketing surveillance, and adverse event reports that pointed to dangers such as stomach paralysis, intestinal obstruction, and permanent vision damage
SGLT-2i works by reducing the reabsorption of glucose by the kidneys, leading to increased glucose excretion in the urine [5]
If you qualify for the program, your first injection will be administered during your initial visit
Stites W, Wang L, Gatlin DM III
SURMOUNT-REAL UK, press release, 14 October 2024: Greater Manchester plans to partner with industry on a new study to deepen understanding of a weight loss medication - Health Innovation Manchester